Entering text into the input field will update the search result below

Ampio posts encouraging results from Ampion COVID-19 pre-clinical study

  • Ampio Pharmaceuticals (AMPE) announces results of a pre-clinical study demonstrating that Ampion inhibits an important pro-inflammatory pathway in the types of immune cells implicated in COVID-19 and Lupus Nephritis, a condition that causes inflammation of the kidney.
  • The aim of the study

Recommended For You

More Trending News

About AMPE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AMPE--
Ampio Pharmaceuticals, Inc.